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Objective. Variation in the position of the liver between preablation and postablation CT images hampers assessment of treatment
of colorectal liver metastasis (CRLM). The aim of this study was to test the hypothesis that discordant preablation and postablation
imaging is associated with more ablation site recurrences (ASRs). Methods. Patients with CRLM were included. Index-tumor size,
location, number, RFA approachs and ablative margins were obtained on CT scans. Preablation and postablation CT images were
assigned a “Similarity of Positioning Score” (SiPS). A suitable cutoﬀ was determined. Images were classified as identical (SiPS-id)
or nonidentical (SiPS-diﬀ). ASR was identified prospectively on follow-up imaging. Results. Forty-seven patients with 97 tumors
underwent 64 RFA procedures (39 patients/63 tumors open RFA, 25 patients/34 tumours CT-targeted RFA, 12 patients underwent
>1 RFA). Images of 52 (54%) ablation sites were classified as SiPS-id, 45 (46%) as SiPS-diﬀ. Index-tumor size, tumor location
and number, concomitant partial hepatectomy, and RFA approach did not influence the SiPS. ASR developed in 11/47 (23%)
patients and 20/97 (21%) tumours. ASR occurred less frequently after open RFA than after CT targeted RFA (P < 0.001). ASR
was associated with larger index-tumour size (18.9 versus 12.8mm, P = 0.011). Cox proportional hazard model confirmed SiPS-
diﬀ, index-tumour size >20mm and CT-targeted RFA as independent risk factors for ASR. Conclusion. Variation in anatomical
concordance between preablation and postablation images, index-tumor size, and a CT-targeted approach are risk factors for ASR
in CRLM.
1. Introduction
Liver metastases develop in approximately 50% of patients
with colorectal carcinoma. Partial hepatectomy is a potential
curative treatment, but only 10–20% of the patients are eligi-
ble for partial hepatectomy. Radiofrequency ablation (RFA)
is an alternative for patients with unresectable tumours
and is often used as an adjunct to partial hepatectomy
[1–4]. By using an image-guided approach, electrodes are
positioned in the tumour either percutaneously or by an
open approach [5–8]. One of the major problems with RFA
is incomplete ablation, leading to ablation site recurrences
(ASRs) [9]. Factors associated with low ASR rates are small
index-tumour size [10], low number of treated tumours [11],
at least 10mm margins of coagulation around the tumour
[1, 12], open surgical approach (versus percutaneous CT-
targeted approach) [2, 3], and tumor location distant from
large vessels [2, 3]. The purpose of post-RFA imaging is the
early detection of ASR, providing the opportunity to repeat
the RFA procedure. Strategies used for post-RFA evaluation
include measuring the ablative margins or focusing on
contrast enhancement in the ablation zone. A disadvantage
of these techniques is the variation that can occur in the
position of the liver between the pre-RFA scan and the post-
RFA scan, resulting in an inaccurate quantitative assessment
of the ablative margin. This may give false reassurance to
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the adequacy of the treatment and might thus be an indirect
risk factor for development of ASR. In this study, we test the
hypothesis that variation in the position of the liver between
pre-RFA scan and post-RFA scan makes the assessment
of completeness of ablation of colorectal liver metastases
diﬃcult, and as an indirect risk factor is associated with the
development of future ablation site recurrences (ASRs).
2. Patients and Methods
2.1. Patients. The study was approved by our institutional
review board. Between July 2000 and July 2008, 142 RFA pro-
cedures were performed for primary (benign and malignant)
and secondary liver tumours in our center. Sixty-five percent
of these procedures were done with an open approach, 35%
was performed percutaneously under CT targeting. Open
procedures were performed in patients who also underwent
a partial hepatectomy or if the tumour could not be safely
reached using the percutaneous route. Laparoscopic proce-
dures were not performed. All procedures were performed
by one of the authors, an experienced hepatobiliary surgeon
in collaboration with dedicated radiologists. CT-targeted
RFA was performed in collaboration with a radiologist.
Fifty-two patients (37%) underwent RFA for colorectal liver
metastases. Five patients were excluded—missing pre-RFA
images (n = 2), multiple and widespread liver metastases
shortly after RFAmaking assessment of ASR impossible (n =
2), and lost to followup (n = 1). Thus, 47 patients who
underwent 64 RFA procedures for 97 liver metastases were
included in the study. Partial hepatectomy was performed
as described previously and is considered the gold standard
[13]. It is standard praxis to fix the liver remnant after
partial hepatectomy with the aim to keep the liver remnant
in the same position in order to prevent rotation of the
remaining liver lobe. Rotation can lead to torsion of the
draining hepatic vein and congestion of the liver lobe. RFA
was only performed if partial hepatectomy was not able to
render the liver tumor-free.
2.2. RFA Procedure. RFA was performed by one staﬀ HPB
surgeon (K. P. de Jang) in collaboration with a staﬀ
radiologist (E. J. Van der Jagt) for the CT-guided procedures.
Ablation procedures are performed in our hospital since
1995 with about 20 procedures per year for colorectal liver
metastases. We used the RF 3000 TM Radio Frequency
Ablation System (Boston Scientific, Boston, MA, USA). A
LeVeen electrode of 2, 3.5, 4, or 5 cm diameter was used,
depending on tumour diameter. The RFA electrode was
positioned using ultrasonography in open and CT-guided
in CT-targeted RFA. RFA was applied according to the
protocol of the manufacturer. RFA was continued until
the generation of radiofrequency waves was blocked by the
rise in tissue impedance. Large tumours were treated by
several overlapping positions of the deployed RFA electrode.
Terminology used in this paper is in accordance to the
guidelines given by Goldberg et al. [14].
2.3. CT Protocol. Patients underwent triphasic CT scanning
before the RFA procedure, one week after the RFA procedure,
then at three-monthly intervals during the first two years
and every six months thereafter. CT was performed on a 16-
or 64-slice multidetector CT scanner (somatom Sensation
64, Siemens, Erlangen, Germany). Intravenous contrast
was used, 120mL iodixanol 320mg I/mL (Visipaque 320,
GE Healthcare, Chalfont St Giles, UK), with a flow rate
of 4.0mL/sec. All subjects were scanned in craniocaudal
direction during inspiratory breath-holding. CT images were
acquired in a supine position using a 16 × 1.5 (16-slice)
or 24 × 1.2 (64-slice) collimation, tube potential 120 kV,
tube current time product 130mAs, pitch 1, slice thickness
of 2mm, reconstruction Kernel B30f, and reconstruction
increment 1.5.
2.4. Followup. Followup of the ablated tumours consisted of
CT imaging or F18-fluorodeoxyglucose positron emission
tomography (FDG-PET) when CT imaging was inconclu-
sive. Patients were considered to have recurrences when
there was a typical pattern of contrast enhancement on
CT imaging and/or pathological glucose uptake on PET
scanning.
2.5. Post-RFA Evaluation. Radiological evaluation of the
tumours before and one week after the RFA procedure was
performed on an Aquarius Workstation (version 1.8.3.6,
TeraRecon Inc., San Mateo, CA, USA). Images in axial
and reconstructed coronal planes were used for three-
dimensional measurements and comparison of the pre-RFA
scan and the post-RFA scan (explanation in Figure 1). This
was done by two of the authors (P. G. Kele, E. J. Van der Jagt).
Reliable comparison was only possible when the position
of the liver was identical or almost identical on the pre-
RFA scan and the post-RFA scan. Therefore, a dichotomous
“Similarity of Positioning Score” (SiPS) was developed in
which post-RFA scans were compared to pre-RFA scans.
Post-RFA scans were centrally and blindly classified as SiPS-
identical (SiPS-id, i.e., comparable to the pre-RFA scans,
Figure 2) or SiPS-diﬀerent (SiPS-diﬀ, i.e., not comparable to
the pre-RFA scan, Figure 3). A post-RFA scan was considered
SiPS-id when the vascular configuration (especially hepatic
and portal veins) was identical or nearly identical to that
on the pre-RFA scan. In addition, the projection of the
abdominal organs, bony structures (vertebrae and ribs), and
the position of previously placed surgical clips had to be
identical or nearly identical. When these criteria were not
met, a scan was regarded as SiPS-diﬀ. For validation of
SiPS, one of the authors (P. G. Kele) classified all tumours
twice for intra-observer agreement. Another radiologist with
two years CT experience performed the same classifications
to obtain the interobserver agreement. Ablative margins
>10mm were considered suﬃcient. The smallest margin in
one of the six directions was considered the most imperfect
one. Therefore, tumours with an ablative margin <10mm
in only one of the six directions were regarded as having an
insuﬃcient ablative margin.
2.6. Definition of Ablation Site Recurrence. Progression at the
site of a previously RFA-treated tumour was considered ASR










Figure 1: Explanation of the method of measurement. Schematic representation of the method of measurement of the ablation zone.
Figure 1 representing the axial and coronal view respectively of the tumour (black circle with white T) and the ablation zone (white circle
with black A). Ablative margins were calculated as follows. The distance from the edge of the tumour to the surface of the liver was measured
in all six directions on the pre-RFA scan (continuous line). The same measurements were performed for the post-RFA scan from the edge of
the ablation zone scan to the surface of the liver (dotted line). The ablative margins are the diﬀerence between both distances. The tumour in
the left liver lobe is considered to be incompletely ablated because in one of the six directions the diﬀerence between both distances is zero.
(a) (b)
(c) (d)
Figure 2: Similarity of Positioning Score-identical (SiPS-id). Example of identical (concordant) pre-RFA CT images and post-RFA CT
images, classified as Similarity of Positioning Score-identical (SiPS-id). The pre-RFA CT scan ((a) axial, (b) coronal) and the post-RFA CT
scan ((c) axial, (d) coronal) are well comparable.
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(a) (b)
(c) (d)
Figure 3: Similarity of Positioning Score-diﬀerent (SiPS-diﬀ). Example of nonidentical (discordant) pre-RFA CT-images and post-RFA
CT-images, classified as Similarity of Positioning Score-diﬀerent (SiPS-diﬀ). The pre-RFA CT-scan ((a) axial, (b) coronal) and post-RFA
CT-scan ((c) axial, (d) coronal) are not comparable.
when it met both of the following criteria: (1) growth of a
contrast-enhancing lesion within or directly adjacent to the
ablation zone and (2) the largest diameter of the lesion was in
direct contact with the ablation zone. The latter prerequisite
is to exclude the outgrowth of satellite lesions in the vicinity
of the ablated tumour (Figure 4).
2.7. Statistical Analysis. Chi-square and Fisher’s exact test
were applied to assess the relationship between categorical
variables SiPS (identical versus diﬀerent), RFA approach
(open versus CT-targeted), partial hepatectomy in the his-
tory (yes versus no), number of tumours ablated (<3 versus
≥3), localization of tumours (subcapsular, i.e., <10mm
under the liver capsule, versus central), ablative margins
(>10mm versus <10mm and >5mm versus <5mm), and
ASR (yes versus no). For comparing the continuous variable
index-tumour size between tumours with and without ASR,
Student’s t-test was used after correction for nonnormal
distribution (log transformation). Survival was assessed with
Kaplan-Meier analysis. Variables possibly contributing to
ASR were analyzed by using log-rank test. Cox proportional
hazard model was used to identify independent risk factors
for ASR. Kappa statistics were calculated to test the intraob-
server and interobserver agreement of SiPS. Agreement
was rated as poor (kappa 0–0.2), fair (kappa 0.21–0.40),
moderate (kappa 0.41–0.60), substantial (kappa 0.61–0.80),
or excellent (kappa 0.81–1.0) [15]. The significance level
was set at a P < 0.05 for all tests. Statistical analysis was
performed using SPSS (Statistical Package for Social Sciences
version 16.0 Inc., Chicago, IL, USA).
3. Results
3.1. General Characteristics and Recurrence Patterns. In 47
patients with 97 colorectal liver metastases, 64 RFA proce-
dures were performed. An open approach was used in 39
patients with 63 metastases. Percutaneous CT-targeted RFA
was performed in 25 patients with 34 metastases. There
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Figure 4: Definition of ablation site recurrence. Examples of
ablation site recurrences (ASRs). The largest diameter of both
lesions on the right is in direct contact with the ablation zone.
The lesion on the left is not an ASR, because the center of the line
representing the largest diameter is not in direct contact with the
ablation zone. It is more probably a satellite metastasis which was
already present at the time of the ablation. Outgrowth of this lesion
took place after the RFA procedure. This prerequisite is necessary
to prevent erroneously identified outgrowing satellite lesions in the
close vicinity of the ablated tumour as ASR.
were 12 patients who underwent one or more further RFA
procedures, of which 5 patients had repeat RFA for ASR. ASR
was seen in 11 patients (23%) with 20 metastases (21%).
There were 2 patients (4%) with 3 metastases (3%) who
showed ASR without recurrences elsewhere. Recurrent dis-
ease elsewhere occurred in 33 patients (70%) with 74 ablated
liver metastases (76%) and was concomitant with ASR in
9 patients (19%) with 17 metastases (18%). Recurrence
without ASR was seen in 24 patients (51%) with 57 tumours
(59%) (Table 1). Mean index-tumour size before RFA was
13.9mm (SD 1.8, range 3.9–78.0mm).
3.2. Similarity of Positioning Score (SiPS). After CT-targeted
RFA, 15 of the 34 tumours (44%) were classified as SiPS-id,
the remaining 56% as SiPS-diﬀ. After open RFA, 37 of the
63 tumours (59%) were classified as SiPS-id, the remaining
41% as SiPS-diﬀ. After open RFA with concomitant partial
hepatectomy, 24 tumours were classified as SiPS-id (56%),
the remaining 44% as SiPS-diﬀ. Kappa statistics for intraob-
server agreement were excellent (kappa 0.834, P < 0.001)
and substantial for interobserver agreement (kappa 0.752,
P < 0.001). Index-tumour size, RFA approach, concomi-
tant partial hepatectomy, number of ablated tumours, and
tumour localization were not diﬀerent in the SiPS-diﬀ group
versus the SiPS-id group (Table 2).
3.3. ASR. ASR occurred in 20 of 97 metastases (21%).
Tumours with ASR were larger than tumours without ASR
(18.9mm versus 12.8mm, P = 0.011). ASR was seen in 17
(50%) tumours treated with CT-targeted RFA and 3 (5%)
tumours with open RFA (P < 0.001). ASR was seen in 6
(12%) tumours classified as SiPS-id and 14 (31%) tumours










Deceased 12/47 (26%) —
Partial hepatectomy 34 (72%) 73 (75%)
Before RFAa 5 (15%) 20 (27%)
During RFA 25 (73%) 43 (59%)
After RFA 4 (12%) 10 (14%)
Type of partial hepatectomy (n = 34)
Right-sided hemihepatectomy 12 (35%) —
Left-sided hemihepatectomy 8 (24%) —
Segment 2 and 3 resection 12 (35%) —











Major comorbidity 7 (15%) —
Minimal residual disease 2 (4%) —
Severe steatosis 1 (2%) —
RFA procedures
1 RFA 35 (75%) —
2 RFAs 9 (19%) —
3 RFAs 1 (2%) —
4 RFAs 2 (4%) —
RFA approach (64 procedures)
Open 39 (61%) 63 (65%)
CT targetedb 25 (39%) 34 (35%)
No. of tumors ablated (64 procedures)
1 tumor 44 (69%) —
2 tumors 13 (20%) —
≥3 tumors 7 (11%) —
Recurrence 33 (70%) 74 (76%)
ASRc 11 (23%) 20 (21%)
Repeat RFA for ASR
Yes 5 (11%) 10 (10%)d
No 42 (89%) 87 (90%)
Partial hepatectomy for ASR
Yes 1 (2%) 2 (2%)
No 46 (98%) 95 (98%)
a
RFA: radiofrequency ablation.
bCT targeted: computer tomography targeted.
cASR: ablation site recurrence.
dCT targeted RFA was performed initially in all tumours which underwent
repeated RFA for ASR.
classified as SiPS-diﬀ (P = 0.017). ASR was not diﬀerent in
tumours with ablative margins <5mm (P = 0.464).
Univariate analysis showed more ASR in tumours treated
with CT-targeted RFA (P < 0.001), in tumours classified
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(n = 45) P value








Open RFA (n = 63) 37 (59%) 26 (41%) 0.203
CT-targeted RFA (n = 34) 15 (44%) 19 (56%)
Partial hepatectomy during
RFAc
Yes (n = 43) 24 (56%) 19 (44%) 0.838
No (n = 54) 28 (52%) 26 (48%)
No. of tumours ablatedc
1-2 (n = 70) 40 (57%) 30 (43%) 0.364
≥3 (n = 27) 12 (44%) 15 (56%)
Localizationc
Subcapsular (n = 76) 44 (58 %) 32 (42 %) 0.140
Central (n = 21) 8 (38 %) 13 (62 %)
a
SiPS: Similarity of Positioning Score, identical (SiPS-id) or diﬀerent (SiPS-
diﬀ).
bStudent’s t-test.
cChi-square or Fisher’s exact test.
as SiPS-diﬀ (P = 0.023), and in tumours with an index-
tumour size >20mm (P = 0.009). Tumour localization
(subcapsular versus central) and ablative margins were not
associated with ASR (P = 0.483 and P = 0.576, resp.). Cox
proportional hazard model identified RFA approach, SiPS,
and index-tumour size as independent predictors of ASR.
CT-targeted RFA was associated with the highest risk for
developing ASR, followed by SiPS-diﬀ and an index-tumor
size >20mm (Table 3).
3.4. Survival. Median time of followup was 36 months
(interquartile range 25–49). Median overall survival in the
open RFA group was 40.7 months (95%-CI 23.3–58.2) and
was not statistically diﬀerent for the CT-targeted RFA group
(P = 0.23). As the proportion of disease-free patients in the
latter group was more than 50% at the end of the study,
the median survival could not be estimated. After open RFA,
median disease-free survival was 35.2 months (95%-CI 29.7–
40.7) and 32.6 months (95%-CI 15.8–49.5) after CT-targeted
RFA (P = 0.50).
4. Discussion
RFA is increasingly used in patients with malignant liver
tumors in whom partial hepatectomy is not able to render
the liver tumor-free. RFA seems to be a highly attrac-
tive treatment modality since it is associated with lower
morbidity and mortality compared to partial hepatectomy.
However, a major concern is the reported high incidence
of ablation site recurrences (ASRs). Early evaluation of the
completeness of RFA—followed by immediate repeated RFA
Table 3: Cox proportional hazard model showing the relative






Open RFA 1.0 0.001
CT-targeted RFA 9.5 (2.6–34.0)






in case of an incomplete procedure—is essential to reduce
the high incidence of ASR. A prerequisite for evaluation of
the completeness of RFA is the anatomical concordance or
comparability of the pre-RFA scan with the post-RFA scan.
In the present study, we hypothesized that incomparability
of the pre-RFA scan and the post-RFA scan may result in
an increased number of future ASR, since completeness
of ablation cannot be evaluated reliably. Indeed we found
that this incomparability is a risk factor associated with
ASR. Other risk factors were CT-targeted RFA approach (as
opposed to open RFA) and an index-tumour size >20mm.
The reason for using the Similarity of Positioning Score
(SiPS) in this study was to evaluate the problem and
consequences of incomparable pre-RFA imaging and post-
RFA imaging. Fifty-four percent of the post-RFA scans were
classified as anatomically concordant or SiPS-identical (SiPS-
id), the remaining 46% as anatomically discordant or SiPS-
diﬀerent (SiPS-diﬀ). Open RFA and CT-targeted RFA were
equally represented, suggesting that SiPS is not influenced
by RFA approach and concomitant partial hepatectomy.
Although intuitively it seems reasonable to expect that partial
hepatectomy is associated with a change in position and
configuration of the liver and thus influence SiPS, we did
not encounter this. A probable explanation is that the liver
remnant is fixed in position at the end of the operation. This
means that SiPS is determined by other factors, for example,
changes in the position of the liver as a result of longitudinal
or rotational movements of the liver related to variations in
diaphragm position. These factors could result in substantial
organ position diﬀerences. These issues are well known in the
field of radiotherapy and nuclear medicine. In radiotherapy,
this problem is improved by using implanted markers which
optimize accurate tumour targeting and advanced scanning
techniques such as four-dimensional CT planning [16, 17].
In nuclear medicine, movements—particularly respiratory
movements—can result in mismatch between PET and CT
images. Respiratory-motion tracking systems, mathematical
correction models, or scanning correction models and
post-processional motion-correction methods are used to
minimize this problem [18, 19]. These techniques could
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be useful in reducing organ position diﬀerences between
subsequent scans in the post-RFA followup.
Radiological evaluation of RFA procedures can be
performed by diﬀerent strategies. Firstly, ablative margins
can be estimated by fusing pre-RFA images and post-
RFA images. Unfortunately, this method is often hindered
by incomparable pre-RFA images and post-RFA images.
Secondly, comparing surfaces, volumes, or diameters of
the index tumor and post-RFA ablation zone is often not
reliable because of geometrical constraints or incomplete
overlap of the index tumor and ablation zone [7, 20].
Thirdly, evaluation can be performed by focusing on post-
RFA contrast enhancement, which might be misleading
because of contrast enhancement associated with post-RFA
inflammation and contrast enhancement due to residual
tumour origin. Diﬀerentiation between these entities can be
performed by their diﬀerent morphological characteristics
and contrast-enhancement patterns on multiphase CT scan-
ning [21, 22], but remains diﬃcult.
A possible solution to detect residual tumour after RFA
without being hindered by incomparable pre-RFA images
and post-RFA images is to perform PET-CT. PET is reported
to have a high diagnostic accuracy in detecting residual
tumour after RFA compared to contrast-enhanced CT and
even MRI, modalities which are more readily available
[21, 23]. Until now, only few studies with small patient
populations assessed the usefulness of PET-CT after RFA.
Based on our study it might be that PET-CT is the preferred
imaging modality to detect incomplete ablations in patients
with discordant pre-RFA scans and post-RFA scans. A
potential limitation might be a false-positive result because
of glucose uptake associated with post-RFA inflammation
in the early post-RFA period [24]. Another possibility to
evaluate the completeness of the ablation is to monitor
ablation zone volume on consecutive CT scans, since an
ongoing decline in ablation zone volume on consecutive
scans is highly predictive of complete ablation and that an
increase in volume is associated with ASR [25]. However,
this is only noticed later in the followup and not on the
first postprocedural scan. Therefore, we recommend that
in case of SiPS-id, patients undergo regular followup with
multiphase CT scanning every three months in the first
two years after the RFA procedure and biannually thereafter.
Patients with SiPS-diﬀ should be followed in a similar
fashion, but it might be advisable in these patients to
perform additional PET-CT scanning three to six months
after the RFA procedure, when the post-RFA inflammation
has subsided and eventual glucose uptake can be attributed
to the residual tumour.
We report an ASR rate of 23% per patient and 21% on
a tumour basis. Previously reported ASR rates vary widely
between 1.8 and 55% [2, 3, 11, 26–28]. We found more ASR
in tumours with SiPS-diﬀ classified scans, CT-targeted RFA
treated tumours and tumours with a diameter of >20mm.
Although some studies have shown a higher incidence of ASR
with ablation margins <10mm [29–31], our findings are in
line with that of others who have reported that ASR is not
related to ablative margins [31, 32]. Unfortunately, authors
often do not mention their evaluation methods, which may
lead to contradictory reports because of the use of diﬀerent
techniques.
It has been reported that CT-targeted RFA is associated
with a higher risk of ASR [2, 3, 12, 26, 28, 33–35], which
is in accordance with our results. The most important
explanation for the higher ASR rate in CT-targeted RFA
is limited access to the tumour compared to open RFA,
leading to inadequate ablation. Open RFA allows complete
mobilization of the liver, better electrode accessibility, addi-
tional manoeuvres (Pringle), and tumour visibility (using
intraoperative ultrasound). Especially relevant is our finding
that despite the higher incidence of ASR in CT-targeted RFA,
survival is not diﬀerent from patients treated with open RFA.
This can very likely be explained by thorough postprocedural
followup. By carefully monitoring patients, early detection
of ASR oﬀers the possibility of timely interventions such as
repeat RFA or partial hepatectomy.
This study has certain limitations. Firstly, the newly
introduced SiPS classification system is used in a small
patient population. We are planning to validate the SiPS
classification in a larger patient cohort. Secondly, we did
not perform biopsies to confirm the diagnosis of ASR.
However, the reason not to do so is well founded—biopsies
can be associated with tumour seeding. This risk outweighs
the benefit of the procedure [36, 37]. Although SiPS was
described in a relative small population encompassing 97
tumours, it is highly reproducible as reflected by the excellent
intraobserver and substantial interobserver agreement.
In conclusion, lack of anatomical concordance between
pre-RFA images and post-RFA images, CT-targeted RFA,
and index-tumour size >20mm are independent risk factors
associated with future ablation site recurrences. Anatomical
concordance of pre-RFA images and post-RFA images,
expressed in the Similarity of Positioning Score, is important
in evaluating the RFA procedure. In discordant scans, no
reliable judgement can be made about the completeness of
ablation and thus whether an additional RFA is necessary.
Therefore, it is associated with an indirect increased risk of
future ablation site recurrences.
Acknowledgment
The authors gratefully acknowledge Dr. Ewen Harrison for
critically reading their paper.
References
[1] E. Berber and A. Siperstein, “Local recurrence after laparo-
scopic radiofrequency ablation of liver tumors: an analysis of
1032 tumors,” Annals of Surgical Oncology, vol. 15, no. 10, pp.
2757–2764, 2008.
[2] S. Mulier, Y. Ni, J. Jamart, T. Ruers, G. Marchal, and L. Michel,
“Local recurrence after hepatic radiofrequency coagulation:
multivariate meta-analysis and review of contributing factors,”
Annals of Surgery, vol. 242, no. 2, pp. 158–171, 2005.
[3] S. Mulier, T. Ruers, J. Jamart, L. Michel, G. Marchal, and Y.
Ni, “Radiofrequency ablation versus resection for resectable
colorectal liver metastases: time for a randomized trial? An
update,” Digestive Surgery, vol. 25, no. 6, pp. 445–460, 2009.
8 International Journal of Hepatology
[4] K. P. De Jong and M. W. J. L. A. E. Wertenbroek, “Liver
resection combined with local ablation: where are the limits?”
Digestive Surgery, vol. 28, no. 2, pp. 127–133, 2011.
[5] M. W. J. L. A. E. Wertenbroek, T. P. Links, T. R. Prins,
J. T. M. Plukker, E. J. van der Jagt, and K. P. de Jong,
“Radiofrequency ablation of hepatic metastases from thyroid
carcinoma,” Thyroid, vol. 18, no. 10, pp. 1105–1110, 2008.
[6] A. R. Gillams and W. R. Lees, “Radio-frequency ablation
of colorectal liver metastases in 167 patients,” European
Radiology, vol. 14, no. 12, pp. 2261–2267, 2004.
[7] E. Paulet, C. Aube´, P. Pessaux et al., “Factors limiting complete
tumor ablation by radiofrequency ablation,” CardioVascular
and Interventional Radiology, vol. 31, no. 1, pp. 107–115, 2008.
[8] I. J. Park, H. C. Kim, C. S. Yu, P. N. Kim, H. J. Won,
and J. C. Kim, “Radiofrequency ablation for metachronous
liver metastasis from colorectal cancer after curative surgery,”
Annals of Surgical Oncology, vol. 15, no. 1, pp. 227–232, 2008.
[9] K. P. De Jong, “What is new in liver surgery? Focus on ther-
moablation and the relevance of the inflammatory response,”
Minerva Chirurgica, vol. 66, pp. 561–572, 2011.
[10] A. Stang, R. Fischbach, W. Teichmann, C. Bokemeyer, and D.
Braumann, “A systematic review on the clinical benefit and
role of radiofrequency ablation as treatment of colorectal liver
metastases,” European Journal of Cancer, vol. 45, no. 10, pp.
1748–1756, 2009.
[11] L. M. Sutherland, J. A. R. Williams, R. T. A. Padbury, D.
C. Gotley, B. Stokes, and G. J. Maddern, “Radiofrequency
ablation of liver tumors: a systematic review,” Archives of
Surgery, vol. 141, no. 2, pp. 181–190, 2006.
[12] F. Burdio, S. Mulier, A. Navarro et al., “Influence of approach
on outcome in radiofrequency ablation of liver tumors,”
Surgical Oncology, vol. 17, no. 4, pp. 295–299, 2008.
[13] K. P. de Jong, A. S. H. Gouw, P. M. J. G. Peeters et al., “P53
mutation analysis of colorectal liver metastases: relation to
actual survival, angiogenic status, and p53 overexpression,”
Clinical Cancer Research, vol. 11, no. 11, pp. 4067–4073, 2005.
[14] S. N. Goldberg, C. J. Grassi, J. F. Cardella et al., “Image-guided
tumor ablation: atandardization of terminology and reporting
criteria,” Journal of Vascular and Interventional Radiology, vol.
20, no. 7, pp. S377–S390, 2009.
[15] J. R. Landis and G. G. Koch, “The measurement of observer
agreement for categorical data,” Biometrics, vol. 33, no. 1, pp.
159–174, 1977.
[16] O. Dawood, A. Mahadevan, and K. A. Goodman, “Stereotactic
body radiation therapy for liver metastases,” European Journal
of Cancer, vol. 45, no. 17, pp. 2947–2959, 2009.
[17] R. D. Timmerman, C. S. Bizekis, H. I. Pass et al., “Local
surgical, ablative, and radiation treatment of metastases,” CA
Cancer Journal for Clinicians, vol. 59, no. 3, pp. 145–170, 2009.
[18] D. W. Townsend, “Positron emission tomography/computed
tomography,” Seminars in Nuclear Medicine, vol. 38, no. 3, pp.
152–166, 2008.
[19] S. A. Nehmeh and Y. E. Erdi, “Respiratory motion in positron
emission tomography/computed tomography: a review,” Sem-
inars in Nuclear Medicine, vol. 38, no. 3, pp. 167–176, 2008.
[20] G. D. Dodd, M. S. Frank, M. Aribandi, S. Chopra, and K.
N. Chintapalli, “Radiofrequency thermal ablation: computer
analysis of the size of the thermal injury created by overlapping
ablations,” American Journal of Roentgenology, vol. 177, no. 4,
pp. 777–782, 2001.
[21] S. Smith and A. Gillams, “Imaging appearances following
thermal ablation,” Clinical Radiology, vol. 63, no. 1, pp. 1–11,
2008.
[22] S. H. Lee, J. M. Lee, K. W. Kim et al., “Dual-energy
computed tomography to assess tumor response to hepatic
radiofrequency ablation: potential diagnostic value of virtual
noncontrast images and iodine maps,” Investigative Radiology,
vol. 46, no. 2, pp. 77–84, 2011.
[23] H. Kuehl, G. Antoch, H. Stergar et al., “Comparison of
FDG-PET, PET/CT and MRI for follow-up of colorectal
liver metastases treated with radiofrequency ablation: initial
results,” European Journal of Radiology, vol. 67, no. 2, pp. 362–
371, 2008.
[24] P. Veit, G. Antoch, H. Stergar, A. Bockisch, M. Forsting, and
H. Kuehl, “Detection of residual tumor after radiofrequency
ablation of liver metastasis with dual-modality PET/CT: initial
results,” European Radiology, vol. 16, no. 1, pp. 80–87, 2006.
[25] P. G. Kele, K. P. de Jong, and E. J. van der Jagt, “Increase in
volume of ablation zones during follow-up is highly suggestive
of ablation site recurrence in colorectal liver metastases
treated with radiofrequency ablation,” Journal of Vascular and
Interventional Radiology, vol. 23, no. 4, pp. 537–544, 2012.
[26] S. McGrane, S. E. McSweeney, and M. M. Maher, “Which
patients will benefit from percutaneous radiofrequency abla-
tion of colorectal liver metastases? Critically appraised topic,”
Abdominal Imaging, vol. 33, no. 1, pp. 48–53, 2008.
[27] S. Garrean, J. Hering, A. Saied, W. S. Helton, and N. J. Espat,
“Radiofrequency ablation of primary and metastatic liver
tumors: a critical review of the literature,” American Journal
of Surgery, vol. 195, no. 4, pp. 508–520, 2008.
[28] H. Hur, Y. T. Ko, B. S. Min et al., “Comparative study
of resection and radiofrequency ablation in the treatment
of solitary colorectal liver metastases,” American Journal of
Surgery, vol. 197, no. 6, pp. 728–736, 2009.
[29] R. Konopke, S. Kersting, F. Makowiec et al., “Resection of
colorectal liver metastases: is a resection margin of 3mm
enough? A multicenter analysis of the GAST study group,”
World Journal of Surgery, vol. 32, no. 9, pp. 2047–2056, 2008.
[30] T. Wakai, Y. Shirai, J. Sakata et al., “Appraisal of 1 cm
hepatectomy margins for intrahepatic micrometastases in
patients with colorectal carcinoma liver metastasis,” Annals of
Surgical Oncology, vol. 15, no. 9, pp. 2472–2481, 2008.
[31] C. H. Liu, R. S. Arellano, R. N. Uppot, A. E. Samir, D.
A. Gervais, and P. R. Mueller, “Radiofrequency ablation of
hepatic tumours: eﬀect of post-ablation margin on local
tumour progression,” European Radiology, vol. 20, no. 4, pp.
877–885, 2010.
[32] C. Schraml, S. Clasen, N. F. Schwenzer et al., “Diagnostic
performance of contrast-enhanced computed tomography in
the immediate assessment of radiofrequency ablation success
in colorectal liver metastases,” Abdominal Imaging, vol. 33, no.
6, pp. 643–651, 2008.
[33] P. Abitabile, U. Hartl, J. Lange, and C. A. Maurer, “Radiofre-
quency ablation permits an eﬀective treatment for colorectal
liver metastasis,” European Journal of Surgical Oncology, vol.
33, no. 1, pp. 67–71, 2007.
[34] J. Machi, A. J. Oishi, K. Sumida et al., “Long-term outcome
of radiofrequency ablation for unresectable liver metastases
from colorectal cancer: evaluation of prognostic factors and
eﬀectiveness in first- and second-line management,” Cancer
Journal, vol. 12, no. 4, pp. 318–326, 2006.
[35] N. P. Reuter, C. E. Woodall, C. R. Scoggins, K. M. McMasters,
and R. C. G. Martin, “Radiofrequency Ablation vs. Resection
for hepatic colorectal metastasis: therapeutically equivalent?”
Journal of Gastrointestinal Surgery, vol. 13, no. 3, pp. 486–491,
2009.
International Journal of Hepatology 9
[36] O. M. Jones, M. Rees, T. G. John, S. Bygrave, and G.
Plant, “Biopsy of resectable colorectal liver metastases causes
tumour dissemination and adversely aﬀects survival after liver
resection,” British Journal of Surgery, vol. 92, no. 9, pp. 1165–
1168, 2005.
[37] M. S. Metcalfe, F. H. G. Bridgewater, E. J. Mullin, and G.
J. Maddern, “Lesson of the week: useless and dangerous—
fine needle aspiration of hepatic colorectal metastases,” British
Medical Journal, vol. 328, no. 7438, pp. 507–508, 2004.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
